查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953386

基於組織的基因組分析市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Tissue Based Genomic Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基於組織的基因組分析市場預計將從 2025 年的 15.2 億美元成長到 2031 年的 22.5 億美元，複合年成長率達到 6.76%。

該市場由用於檢測腫瘤組織樣本以識別特定基因組變化（例如突變和拷貝數變異）的診斷技術組成，這些變化對於選擇標靶治療至關重要。該市場的主要驅動力是全球癌症發病率的不斷上升，這顯著增加了對精準分子表徵的需求，從而支持個人化醫療。此外，伴隨診斷的監管核准不斷增加以及基因組數據在臨床治療方案中整合程度的提高也推動了該市場的發展。美國癌症協會預測，到2024年，美國新增癌症病例數將首次超過200萬，凸顯了精準診斷工具的緊迫感。

市場概覽
預測期 2027-2031
市場規模：2025年 15.2億美元
市場規模：2031年 22.5億美元
複合年成長率：2026-2031年 6.76%
成長最快的細分市場 定序技術
最大的市場 北美洲

儘管成長勢頭強勁，但由於全面基因組檢測高成本以及不同醫療體系報銷政策不一致，該市場仍面臨許多挑戰。這些經濟限制阻礙了患者獲得檢測的機會，並延緩了這些診斷測試在當地癌症診療機構的常規應用。此外，依賴侵入性切片檢查來確保獲得充足、高品質的組織樣本也帶來了後勤方面的挑戰，因為樣本數量或品質不足會導致檢測失敗，因此無法成功完成基因組分析。

市場促進因素

次世代定序(NGS) 技術的快速發展顯著提升了腫瘤分析的通量、準確性和成本效益，成為全球組織基因組分析市場發展的根本驅動力。從單基因檢測到全面基因組分析 (CGP) 的轉變主要得益於高通量定序平台的應用，這些平台使實驗室能夠有效處理大量的組織數據。這項技術進步使臨床醫生能夠檢測到傳統方法無法識別的複雜標記，例如罕見突變和腫瘤突變負荷 (TMB)。這些先進工具在業界的快速普及顯而易見；例如，Illumina 在其 2024 年 2 月的財報中宣布，其在 2023 會計年度共交付了 352 台 NovaSeq X 儀器，這表明全球基因組實驗室正處於強勁的設備更新周期。

此外，隨著治療成功越來越依賴特定的分子診斷，精準醫療的日益普及和以生物標記為導向的藥物開發平臺的成長正顯著推動市場需求。生物製藥公司正優先開發需要伴隨診斷來識別合適患者的標靶治療，從而將基因組分析整合到標準臨床工作流程中。這一趨勢在監管成果中也得到了體現。 2024年2月，個人化醫療聯盟（PMC）宣布，2023年核准的新藥中將有超過三分之一是個人化藥物，這已是連續第四年實現這一目標。對生物標記指導治療的依賴直接推動了診斷服務提供者的商業性成長。 Exact Sciences公司的案例便是一個例證，該公司報告稱，其精準腫瘤學部門在上年度的收入達到6.29億美元，凸顯了基於組織的基因組檢測在現代癌症治療中的重要經濟作用。

市場挑戰

全球組織基因組分析市場的擴張受到全面基因組檢測高成本和不一致的報銷政策的顯著阻礙。當保險公司拒絕承保或提供的報銷金額不足以涵蓋進行這些複雜檢測的營運成本時，臨床檢查室常常面臨沉重的經濟負擔。這種經濟上的不確定性使得地方癌症中心無法常規進行廣泛的基因組分析，導致市場准入僅限於資金雄厚的學術機構。因此，檢測量持續低於臨床需求，直接抑制了產生收入，並減緩了精準醫療工具的整體應用。

這種財務不穩定也嚴重影響了診斷服務提供者的營運能力，迫使他們在資源分配上做出艱難的抉擇。根據美國病理學家協會 (CAP) 2024 年的數據，在過去五年中，72% 的病理診所主任都受到了報銷率下降的負面影響。這些財務限制迫使實驗室減少人員配備和檢測項目，導致檢測結果返回延遲和服務能力下降。這些由支付機制不完全造成的營運瓶頸，阻礙了市場有效擴張以應對日益嚴重的全球癌症負擔。

市場趨勢

全球基於組織的基因組分析市場正因人工智慧 (AI) 與基因組數據解讀的融合而發生變革，AI 的運用實現了對大規模次世代定序(NGS) 資料集的自動化分析。實驗室正利用 AI 演算法加速變異註釋，並檢測出人工分析可能遺漏的可操作生物標記。這種技術融合正在推動精準腫瘤學的快速發展，而數據驅動的臨床決策支援對於應對複雜全面的基因組分析至關重要。為了反映這一日益成長的需求，Tempus AI 在 2024 年 5 月的註冊聲明中公佈，其 2023 會計年度的收入為 5.32 億美元（同比成長 66%），凸顯了市場對 AI 驅動的精準醫療解決方案的日益成長的需求。

同時，結合DNA和RNA分析的多組體學分析技術的興起，使得人們能夠全面了解腫瘤微環境。這一趨勢超越了簡單的突變檢測，涵蓋了基因表現，從而更深入地揭示了腫瘤異質性和治療抗藥性機制。研究人員和臨床醫生正在利用這些先進工具來最佳化免疫療法的患者分層，推動了對太空生物學技術的顯著投資。這項轉變也得到了顯著的財務成長的支持：2024年2月，10x Genomics宣布全年營收達6.187億美元（年成長20%），這主要得益於太空分析和單細胞分析儀器的應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球基於組織的基因組分析市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過技術（定序技術、免疫組織化學等）
    • 依應用領域（個人化醫療、腫瘤診斷、研究）
    • 按最終用戶（研究機構、臨床研究機構、醫院和診所、診斷檢查室、製藥和生物技術公司、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美組織基因組分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲組織基因組分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區基於組織的基因組分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲基於組織的基因組分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美組織基因組分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球組織基因組分析市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Foundation Medicine Inc
  • Illumina, Inc.
  • QIAGEN NV
  • Roche Diagnostics Corp
  • Thermo Fisher Scientific Inc.
  • Exact Sciences Corp
  • Personal Genome Diagnostics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23890

The Global Tissue Based Genomic Profiling Market is projected to expand from USD 1.52 Billion in 2025 to USD 2.25 Billion by 2031, achieving a CAGR of 6.76%. This market consists of diagnostic technologies that examine tumor tissue samples to identify specific genomic changes, such as mutations and copy number variations, which are essential for selecting targeted therapies. A key factor driving this market is the rising global incidence of cancer, which creates a critical need for precise molecular characterization to support personalized medicine. Furthermore, the market is bolstered by the increasing regulatory approvals for companion diagnostics and the incorporation of genomic data into clinical treatment planning. Highlighting the urgency for accurate diagnostic tools, the American Cancer Society projected in 2024 that new cancer cases in the United States would surpass 2 million for the first time.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.52 Billion
Market Size 2031USD 2.25 Billion
CAGR 2026-20316.76%
Fastest Growing SegmentSequencing Techniques
Largest MarketNorth America

Despite this positive growth trajectory, the market faces significant obstacles due to the high costs of comprehensive genomic testing and the lack of consistent reimbursement policies across various healthcare systems. These financial limitations often restrict patient access and slow the routine implementation of these diagnostic tests within community oncology practices. Additionally, the dependence on invasive biopsies to secure adequate high-quality tissue samples poses a logistical challenge, as insufficient sample quantity or quality can result in test failure and prevent the successful completion of genomic assays.

Market Driver

Rapid progress in Next-Generation Sequencing (NGS) technologies serves as a foundational driver for the Global Tissue Based Genomic Profiling Market, improving the throughput, accuracy, and cost-efficiency of tumor analysis. The transition from single-gene testing to comprehensive genomic profiling (CGP) is primarily powered by the adoption of high-capacity sequencing platforms that enable laboratories to process large volumes of tissue data effectively. This technological advancement allows clinicians to detect rare mutations and complex markers, such as Tumor Mutational Burden (TMB), which were previously unidentifiable using standard methods. The industry's rapid uptake of these advanced tools is evident; for instance, Illumina reported in its February 2024 financial results that it shipped 352 NovaSeq X instruments during the fiscal year 2023, indicating a strong equipment upgrade cycle in genomic labs worldwide.

Moreover, the increasing adoption of precision medicine and the growth of biomarker-focused drug development pipelines significantly boost market demand, as therapeutic success increasingly relies on specific molecular diagnoses. Biopharmaceutical companies are prioritizing the creation of targeted therapies that require companion diagnostics to identify suitable patients, thereby integrating genomic profiling into standard clinical workflows. This trend is highlighted by regulatory achievements; the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented over one-third of all new drug approvals in 2023 for the fourth consecutive year. This dependence on biomarker-guided treatment directly fuels commercial growth for diagnostic providers, as demonstrated by Exact Sciences, which reported $629 million in revenue from its Precision Oncology segment in 2024 for the prior year, underscoring the vital economic role of tissue-based genomic testing in modern cancer care.

Market Challenge

The expansion of the Global Tissue Based Genomic Profiling Market is significantly hindered by the substantial costs associated with comprehensive genomic testing combined with inconsistent reimbursement policies. Clinical laboratories frequently encounter severe financial strain when insurance providers deny coverage or offer reimbursement rates that do not cover the operational expenses of performing these complex assays. This financial uncertainty discourages community oncology practices from routinely ordering broad genomic profiles, effectively restricting market access to well-funded academic centers. Consequently, the volume of tests conducted remains lower than clinical demand, which directly suppresses revenue generation and slows the overall adoption of precision medicine tools.

This financial instability also severely impacts the operational capabilities of diagnostic providers, necessitating difficult decisions regarding resource allocation. Data from the College of American Pathologists in 2024 revealed that 72% of pathology practice leaders experienced negative impacts from declining reimbursement rates over the previous five years. Such fiscal constraints force laboratories to reduce staffing or curtail their test menus, leading to slower turnaround times and diminished service availability. These operational bottlenecks, driven by inadequate payment mechanisms, prevent the market from scaling efficiently to meet the rising global burden of cancer.

Market Trends

The Global Tissue Based Genomic Profiling Market is being transformed by the integration of Artificial Intelligence (AI) for genomic data interpretation, which automates the analysis of extensive NGS datasets. Laboratories are increasingly utilizing AI algorithms to speed up variant annotation and detect actionable biomarkers that manual analysis might miss. This technological convergence facilitates the rapid scaling of precision oncology, making data-driven clinical decision support essential for managing the complexity of comprehensive profiles. Reflecting this growing demand, Tempus AI reported in its May 2024 registration statement that it generated USD 532 million in revenue for the fiscal year 2023, a 66% increase from the prior year, highlighting the appetite for AI-enabled precision medicine solutions.

Concurrently, the rise of multi-omics profiling, which combines DNA and RNA analysis, is providing a comprehensive view of the tumor microenvironment. This trend moves beyond simple mutation detection to include gene expression signatures, offering deeper insights into tumor heterogeneity and therapeutic resistance mechanisms. Researchers and clinicians are leveraging these advanced tools to refine patient stratification for immunotherapies, driving substantial investment in spatial biology technologies. This shift is confirmed by significant financial growth; 10x Genomics announced in February 2024 that its full-year revenue for 2023 reached USD 618.7 million, a 20% increase from 2022, fueled by the adoption of its spatial and single-cell profiling instruments.

Key Market Players

  • Foundation Medicine Inc
  • Illumina, Inc.
  • QIAGEN N.V.
  • Roche Diagnostics Corp
  • Thermo Fisher Scientific Inc.
  • Exact Sciences Corp
  • Personal Genome Diagnostics Inc.

Report Scope

In this report, the Global Tissue Based Genomic Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Based Genomic Profiling Market, By Technology

  • Sequencing Techniques
  • Immunohistochemistry
  • Others

Tissue Based Genomic Profiling Market, By Application

  • Personalized Medicine
  • Oncological Diagnostics
  • Research

Tissue Based Genomic Profiling Market, By End-User

  • Research Institutes
  • Clinical Research Organizations
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others

Tissue Based Genomic Profiling Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Based Genomic Profiling Market.

Available Customizations:

Global Tissue Based Genomic Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Based Genomic Profiling Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sequencing Techniques, Immunohistochemistry, Others)
    • 5.2.2. By Application (Personalized Medicine, Oncological Diagnostics, Research)
    • 5.2.3. By End-User (Research Institutes, Clinical Research Organizations, Hospitals & Clinics, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Tissue Based Genomic Profiling Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tissue Based Genomic Profiling Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Tissue Based Genomic Profiling Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Tissue Based Genomic Profiling Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Tissue Based Genomic Profiling Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tissue Based Genomic Profiling Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Tissue Based Genomic Profiling Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Tissue Based Genomic Profiling Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Tissue Based Genomic Profiling Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Tissue Based Genomic Profiling Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia Pacific Tissue Based Genomic Profiling Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tissue Based Genomic Profiling Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Tissue Based Genomic Profiling Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Tissue Based Genomic Profiling Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Tissue Based Genomic Profiling Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Tissue Based Genomic Profiling Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Tissue Based Genomic Profiling Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tissue Based Genomic Profiling Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Tissue Based Genomic Profiling Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Tissue Based Genomic Profiling Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. South America Tissue Based Genomic Profiling Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tissue Based Genomic Profiling Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Tissue Based Genomic Profiling Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Tissue Based Genomic Profiling Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tissue Based Genomic Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Foundation Medicine Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Illumina, Inc.
  • 15.3. QIAGEN N.V.
  • 15.4. Roche Diagnostics Corp
  • 15.5. Thermo Fisher Scientific Inc.
  • 15.6. Exact Sciences Corp
  • 15.7. Personal Genome Diagnostics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer